APGE - NASDAQ
Apogee Therapeutics, Inc.
$84.19
+3.0%Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotApogee Therapeutics, Inc. Management Team
Dr. Rebecca Dabora Ph.D.
Chief Development Officer
Dr. Michael Thomas Henderson M.D.
Chief Executive Officer & Director
Compensation
$1,207,238
Ms. Jane Pritchett V. Henderson
Chief Financial Officer
Compensation
$879,375
Mr. Matthew Batters J.D.
Chief Legal Officer & Corporate Secretary
Dr. Carl Linden Dambkowski M.D.
Chief Medical Officer
Compensation
$879,375
Ms. Emily Cox
SVice President & Head of People
Dr. Drew Badger Ph.D.
Senior Vice President and Head of Regulatory Affairs & Toxicology
Ms. Wendy Aspden-Curran
Senior Vice President of Clinical Operations
Ms. Monica Forbes
Senior Vice President of Finance
Ms. Noel Kurdi
Vice President of Investor Relations
Apogee Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $145.12M worth of APGE shares, with no buying activity reported.
3 Months
0
0.00
56.0K
4.57M
-4.6M
-$4.57M
3-6 Months
0
0.00
1.8M
135.82M
-135.8M
-$135.82M
6-9 Months
0
0.00
62.8K
4.47M
-4.5M
-$4.47M
9-12 Months
0
0.00
6.4K
245.50K
-245K
-$245K
Top Buyers
No buying activity
Top Sellers
Fairmount Funds Management Llc
Director
$133.53M
Henderson Michael Thomas
Director, Officer: Chief Executive Officer
$8.17M
Dambkowski Carl
Officer: Chief Medical Officer
$2.46M
Henderson Jane
Officer: Chief Financial Officer
$964K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $145.12M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
APGE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 05, 2024 | 2024 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.